Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history DOI Creative Commons
Jin Hwa Kim, Young Sang Lyu, Bongseong Kim

et al.

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(7), P. 2567 - 2577

Published: April 21, 2024

To evaluate the effects of initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors on cardiorenal outcomes and mortality compared to dipeptidyl peptidase-4 (DPP-4) as active comparators in patients diagnosed with type 2 diabetes a history percutaneous coronary intervention (PCI).

Language: Английский

The Quest for Understanding Diabetic Cardiomyopathy DOI
Anuradha Lala, Robert J. Mentz, Carlos G. Santos‐Gallego

et al.

Journal of the American College of Cardiology, Journal Year: 2024, Volume and Issue: 84(2), P. 149 - 151

Published: June 17, 2024

Language: Английский

Citations

3
The Beneficial Effect of the SGLT2 Inhibitor Dapagliflozin in Alleviating Acute Myocardial Infarction-Induced Cardiomyocyte Injury by Increasing the Sirtuin Family SIRT1/SIRT3 and Cascade Signaling DOI Open Access
Yi‐Hsiung Lin, Wei‐Chung Tsai, Chien‐Chih Chiu

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(15), P. 8541 - 8541

Published: Aug. 5, 2024

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have a variety of cardiovascular and renoprotective effects been developed as novel agents for the treatment heart failure. However, beneficial mechanisms SGLT2i on cardiac tissue need to be investigated further. In this study, we established mouse model acute myocardial infarction (AMI) using coronary artery constriction surgery role dapagliflozin (DAPA) in protecting cardiomyocytes from hypoxic injury induced by AMI. vitro experiments were done cultured H9c2 ventricular cells verify potential mechanism. Expression SIRT family related genes proteins was verified qPCR, Western blotting immunofluorescence staining, intrinsic mechanism cardiomyocyte death due AMI hypoxia comprehensively RNA sequencing. The sequencing results mice showed that may mainly involved hypoxia-induced death. conferring resistance cardiomyocytes. It SIRT1/3/6 downregulated environment, addition significantly increased gene protein expression SIRT1, 3 6. We then underlying RNA-seq, found upregulated downregulation, which includes

Language: Английский

Citations

3
Salvianolic acids and its potential for cardio-protection against myocardial ischemic reperfusion injury in diabetes DOI Creative Commons
Yuxin Jiang, Yin Cai,

Ronghui Han

et al.

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 12, 2024

The incidence of diabetes and related mortality rate increase yearly in modern cities. Additionally, elevated glucose levels can result an reactive oxygen species (ROS), ferroptosis, the disruption protective pathways heart. These factors collectively heighten vulnerability diabetic individuals to myocardial ischemia. Reperfusion therapies have been effectively used clinical practice. There are limitations current methods treat ischemia-reperfusion injury. As a result, reducing post-treatment ischemia/reperfusion injury remains challenge. Therefore, efforts underway provide more efficient therapy. Salvia miltiorrhiza Bunge (Danshen) has for centuries ancient China cardiovascular diseases (CVD) with rare side effects. Salvianolic acid is water-soluble phenolic compound potent antioxidant properties greatest hydrophilic property Danshen. It recently discovered that salvianolic acids A (SAA) B (SAB) capable inhibiting apoptosis by targeting JNK/Akt pathway NF-κB pathway, respectively. This review delves into most recent discoveries regarding therapeutic cardioprotective benefits diabetes. shows great potential protection mellitus. thorough understanding mechanism could expand its uses developing medicines treating mellitus ischemia-reperfusion.

Language: Английский

Citations

2
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance DOI Creative Commons
Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: March 11, 2024

Abstract Originally designed as anti-hyperglycemic drugs, Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated protective cardiovascular effects, with significant impact on morbidity mortality. Despite several mechanisms been proposed, the exact pathophysiology behind these effects is not yet fully understood. Cardiovascular imaging key for evaluation of diabetic patients, an established role from identification early subclinical changes to long-term follow up prognostic assessment. Among different modalities, CMR may a key-role being gold standard volumes function assessment having unique ability provide tissue characterization. Novel techniques are also implementing possibility evaluate cardiac metabolism through thereby further increasing potential modality in this context. Aim paper comprehensive review parameters novel applied both pre-clinical clinical studies evaluating SGLT2i GLP-1Ra, their better understanding underlying CV drugs.

Language: Английский

Citations

2
Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history DOI Creative Commons
Jin Hwa Kim, Young Sang Lyu, Bongseong Kim

et al.

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(7), P. 2567 - 2577

Published: April 21, 2024

To evaluate the effects of initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors on cardiorenal outcomes and mortality compared to dipeptidyl peptidase-4 (DPP-4) as active comparators in patients diagnosed with type 2 diabetes a history percutaneous coronary intervention (PCI).

Language: Английский

Citations

2